EFFICACY AND SAFETY OF GABAPENTIN AND PREGABALIN IN CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY
INTRODUCTION: Chemotherapy Induced Peripheral Neuropathy (CIPN) occurs as a common Adverse Drug Reaction (ADR) of anti-cancer drugs. The prevalence varies from 10 to 100%. To date, there is no standard effective treatment protocol for this condition. However, the neuro-modulators like gabapentin and pregabalin are increasingly being used to treat CIPN. With this background this study was undertaken to compare the efficacy and safety of gabapentin and pregabalin in CIPN.
METHODS: This study was conducted in the department of medical oncology at Vydehi Institute of Medical Sciences and Research Centre, Bangalore. It was initiated after the approval from Institutional Ethics Committee (IEC). After obtaining written informed consent, the participants were randomized into two groups. Group A received gabapentin, 300mg orally and group B received pregabalin 75mg orally; twice daily for 8 weeks. They were followed up at 2, 4 and 8 weeks. The intensity and quality of pain was assessed by Visual Analogue Scale (VAS) and Pain Quality Assessment Scale (PQAS). Safety was assessment by ADR. Data was analyzed using Student's t test and Mann-Whitney U test. A p-value of 0.05 or less was considered as statistically significant.
RESULTS: Reduction in VAS and PQAS scores at 8 weeks were statistically significant in each group (p< 0.0001). The ADR common to both the groups were drowsiness and sedation. The prevalence of ADR was more in the gabapentin group.
CONCLUSION: Both gabapentin and pregabalin have similar clinical efficacy in the treatment of CIPN. The prevalence of ADR was higher in gabapentin group compared to pregabalin group.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.